A cross-sectional observational protocol will enrol 200 adults (age ≥18) at a tertiary academic hospital in Cape Town. The study groups are predefined: 80 participants with resistant hypertension, 80 with non-resistant hypertension, and 40 normotensive controls. Investigators will recruit from a hypertension clinic, general medical wards and a hospital staff cohort; consecutive eligible patients will be approached during routine visits. The study team reported plans to match groups by age, sex, ethnicity and socioeconomic status where possible. Written informed consent will be obtained and clinical information verified through chart review.
Blood pressure classification follows established clinical criteria: resistant hypertension is defined as elevated blood pressure despite three antihypertensive agents of different classes including a diuretic, or blood pressure controlled on four or more agents; non-resistant hypertension denotes controlled blood pressure on three or fewer agents; normotension is absence of hypertension and no antihypertensive therapy.
Participants will provide blood, urine and saliva samples according to a standardized protocol. The point-of-care exposure metric is the Pylori DuoTect® assay, which detects antibodies to CagA and FliD; investigators noted that FliD will serve as a marker of exposure while CagA provides information about a virulence-associated antigen. Downstream blood assays will include lipid profiles, inflammatory and nitric oxide–related markers, homocysteine, insulin indices, complete blood count, ghrelin quantification, multiplex cytokine profiling and flow cytometric immunophenotyping of peripheral blood mononuclear cells. PAXgene® blood RNA samples will be retained for potential future transcriptomic analyses.
Saliva sampling will undergo exploratory antigen testing using CerTest® kits; the protocol explicitly states these kits are validated for stool rather than saliva, and that saliva antigen results will not be used to define the primary H. pylori exposure variable. Remaining saliva will be stored for possible future oral microbiome analyses that are not specified in the current protocol.
The planned sample size reflects pragmatic recruitment capacity and the exploratory aim of the study. With 80 participants per hypertensive group, the investigators calculated detectable effect-size using a two-sample comparison of proportions (two-sided α = 0.05, 80% power), estimating the ability to detect an absolute between-group seroprevalence difference of approximately 21%. The primary objective is to evaluate associations between serological exposure to H. pylori antigens (CagA, FliD) and hypertension phenotype (resistant versus non-resistant versus normotension).
Multivariable logistic regression will be used to test the primary association, adjusting for demographic, lifestyle and clinical covariates captured in the study case report form. Secondary analyses will characterise clinical, biochemical and immunological differences by exposure status and explore potential mechanistic links between exposure and blood pressure dysregulation.
The study team outlined multiple biologic pathways by which chronic Helicobacter pylori exposure could plausibly influence blood pressure regulation. They cited systemic inflammation, endothelial dysfunction, immune cross-reactivity to vascular antigens (reported for anti-CagA antibodies), altered nitric oxide bioavailability, and metabolic effects such as insulin resistance potentially mediated by disrupted ghrelin synthesis. The protocol references prior observational work and meta-analyses showing modest associations between H. pylori infection and hypertension, and notes limited data specifically addressing resistant hypertension or antigen-specific serology in sub-Saharan African populations.
The inclusion of both CagA and FliD serology aims to capture overall exposure (FliD) alongside exposure to a virulence-associated antigen (CagA). Investigators emphasised that while FliD is an established serological marker of exposure, direct evidence linking FliD itself to cardiovascular disease is not documented in this protocol.
Clinical data will be collected by trained nurses and doctors fluent in English, Afrikaans and isiXhosa, using a Human Research Ethics Committee–approved case report form. Recorded variables include demographics, anthropometrics, lifestyle factors (smoking, alcohol, dietary salt intake), comorbidities (including HIV status), medication history (antihypertensives, statins, proton-pump inhibitors, antibiotics, antiretrovirals, NSAIDs, steroids), family history and vital signs.
The protocol specifies that saliva antigen testing and potential oral microbiome characterisation are exploratory; saliva CerTest® results will not define the primary exposure. The authors stated that no datasets were generated or analysed at the time of manuscript preparation and that all relevant data will be made available upon study completion.
The protocol acknowledges several constraints. The cross-sectional design limits causal inference and temporal resolution between exposure and hypertensive phenotype. The sample size was selected pragmatically and is powered to detect only a relatively large absolute difference (~21%) in seroprevalence between hypertensive groups; smaller differences may go undetected. Saliva antigen testing is exploratory because the CerTest® kits are validated for stool, not saliva, and the protocol does not ascribe primary exposure status to saliva results. The authors did not report specific timelines for analysis, and no proteomic or transcriptomic results are presented because PAXgene® samples are reserved for future exploratory work. These unanswered questions frame the study as hypothesis-generating and indicate areas for future mechanistic and interventional research.